BlackRock
TRVI icon

BlackRock’s Trevi Therapeutics TRVI Stock Holding History

BlackRock’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$208M Buy
11,155,026
+914,840
+9% +$13.3M ﹤0.01% 1773
2026
Q1 		$122M Buy
10,240,186
+114,003
+1% +$1.28M ﹤0.01% 1978
2025
Q4 		$127M Buy
10,126,183
+225,130
+2% +$2.6M ﹤0.01% 1951
2025
Q3 		$90.6M Buy
9,901,053
+1,696,047
+21% +$12.7M ﹤0.01% 2159
2025
Q2 		$44.9M Buy
8,205,006
+2,892,464
+54% +$18M ﹤0.01% 2513
2025
Q1 		$33.4M Buy
5,312,542
+1,384,080
+35% +$6.6M ﹤0.01% 2611
2024
Q4 		$16.2M Buy
3,928,462
+706,710
+22% +$2.26M ﹤0.01% 3174
2024
Q3 		$10.8M Buy
3,221,752
+86,637
+3% +$258K ﹤0.01% 3361
2024
Q2 		$9.34M Buy
3,135,115
+759,406
+32% +$2.11M ﹤0.01% 3420
2024
Q1 		$8.2M Buy
2,375,709
+55,993
+2% +$125K ﹤0.01% 3450
2023
Q4 		$3.11M Buy
2,319,716
+171,453
+8% +$260K ﹤0.01% 3874
2023
Q3 		$4.68M Sell
2,148,263
-86,598
-4% -$196K ﹤0.01% 3679
2023
Q2 		$5.34M Buy
2,234,861
+2,152,616
+2,617% +$5.42M ﹤0.01% 3701
2023
Q1 		$152K Buy
82,245
+1,474
+2% +$3.33K ﹤0.01% 4858
2022
Q4 		$156K Buy
80,771
+21,947
+37% +$43.3K ﹤0.01% 4919
2022
Q3 		$90K Buy
58,824
+1,330
+2% +$4.36K ﹤0.01% 5207
2022
Q2 		$161K Buy
57,494
+24,055
+72% +$59.1K ﹤0.01% 5100
2022
Q1 		$73K Sell
33,439
-11,509
-26% -$11.9K ﹤0.01% 5352
2021
Q4 		$35K Buy
44,948
+1,049
+2% +$1.1K ﹤0.01% 5467
2021
Q3 		$61K Sell
43,899
-281
-0.6% -$498 ﹤0.01% 5254
2021
Q2 		$99K Buy
44,180
+11,786
+36% +$26.5K ﹤0.01% 5052
2021
Q1 		$87K Buy
32,394
+9,357
+41% +$27.4K ﹤0.01% 4855
2020
Q4 		$56K Buy
23,037
+919
+4% +$2.98K ﹤0.01% 4657
2020
Q3 		$89K Sell
22,118
-1,595
-7% -$7.49K ﹤0.01% 4535
2020
Q2 		$155K Buy
23,713
+14,641
+161% +$51.5K ﹤0.01% 4414
2020
Q1 		$30K Buy
9,072
+1,723
+23% +$7.83K ﹤0.01% 4558
2019
Q4 		$28K Buy
7,349
+6,185
+531% +$23.2K ﹤0.01% 4610
2019
Q3 		$5K Sell
1,164
-2,320
-67% -$12.6K ﹤0.01% 4787
2019
Q2 		$26K Buy
+3,484
New +$30K ﹤0.01% 4652

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

BlackRock's TRVI Position: Q2 2026 in Review

BlackRock increased its Trevi Therapeutics (TRVI) stake by 8.9% in Q2 2026, buying an estimated $13.3M and bringing the position to 11,155,026 shares worth $208M. The position accounts for ﹤0.01% of the portfolio, ranked #1773.

BlackRock first reported a position in TRVI in Q2 2019 and has held it in 29 quarters since. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • BlackRock held 11,155,026 shares of Trevi Therapeutics worth $208M as of Q2 2026.
  • BlackRock bought 914,840 Trevi Therapeutics shares in Q2 2026, an estimated $13.3M.
  • Trevi Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #1773 holding.
  • BlackRock first reported a position in Trevi Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.